AbSci

AbSci

AbSci

A company that has developed an E. coli expression system for optimized and scalable antibody and protein production.
Type
B2c
Founded
2011
Raised
$82.1M
Follow us
Alexa global traffic share
Twitter followers
Latest funding Show all
$65,000,000
Venture capital (Series E) - 2020
Redmile Group Phoenix Venture Partners Casdin Capital +1
Team Size
1–10
Employees
neurons.AI

Protein discovery and development platform AbSci files for a $100 million IPO

Acquisition
neurons.AI

Totient, a Viva Biotech Portfolio Company, has been Acquired by AbSci

GeekWire

Biotech startup AbSci raises $125M for ‘Protein Printing’ tech; total funding up to $230M

GeekWire

AbSci acquires AI startup Denovium to boost synthetic biology platform

$65,000,000 Venture capital (Series E)
GeekWire

Synthetic biology startup AbSci raises $65M to expand ‘Protein Printing’ tech

FinSMEs

AbSci Raises $15.4M in Series D Funding

$12,000,000 Venture capital (Series C)
GeekWire , PE HUB , FinSMEs

Biomanufacturing company AbSci raises $12M to scale synthetic biology platform

Funding Science
$5,100,000 Venture capital (Series A)
Columbian.com

Biotech firm secures $5.1M to further work in proteins